IMU - Cash Analysis, page-2

when somebody writes BS we just have to compare the approach

Multiple products in pipeline

Risk Diversification: By developing multiple products, companies spread the risk across different assets. If one product fails in trials, the company has others in the pipeline to balance the setback.
Multiple Revenue Streams: A successful product launch can create cash flow to support the development of other drugs.
Attracting Investment: Investors are generally more comfortable with companies that have a diversified pipeline, as it reduces the binary risk of failure.
Higher Costs: Maintaining multiple products requires more capital for R&D, clinical trials, and manufacturing.
Complex Management: Managing multiple trials and products requires greater coordination, regulatory navigation, and resource allocation.


Single product ( that to beating a dead horse )

High Risk: The company’s entire fate rests on the success or failure of a single product. If the drug fails, the company's value can collapse, leaving it vulnerable to financial failure.
Difficulty Attracting Investment: Investors may view single-product companies as riskier because there is no fallback if the primary product fails in trials.